Tuberculosis

Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study

Date: 
8/17/18
Citation: 

Rajoli RKR, PodanyAT, Moss DM, et al. Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. Int J Tuberc Lung Dis. 2018 Aug 1;22(8):937-944. PMID: 29991405; PMCID: PMC6166436.

SETTING:
Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues.

OBJECTIVE:
niazid, rifapentine, bedaquiline and delamanid—in adults for treatment for latent tuberculous infection (LTBI).

Health Topics: 
LA/ER Implantable Therapy
LA/ER Injectable Therapy
Tuberculosis

    Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?

    Date: 
    8/17/18
    Citation: 

    Dooley KE. Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time? Int J Tuberc Lung Dis. 2018 Aug 1;22(8):833-34. DOI: https://doi.org/10.5588/ijtld.18.0411.

    Tuberculosis (TB) is a wily and enduring foe, responsible for 1 billion deaths in the last 200 years. With the introduction of antibiotics active against Mycobacterium tuberculosis in the 1950s, TB disease could finally be cured with multidrug therapy. TB drugs must still be given for months, generally via directly observed therapy, which is intrusive, expensive, and inconvenient.

    Health Topics: 
    Tuberculosis

      Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges

      Date: 
      2/15/18
      Citation: 

      Swindells S, Siccardi M, Barrett SE, et al. Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges. Int J Tuberc Lung Dis. 2018 Feb 1; 22(2): 125–132. PMID: 29506608; PMCID: PMC6103451.

      Long-acting/extended-release drug formulations have proved very successful in diverse areas of medicine, including contraception, psychiatry and, most recently, human immunodeficiency virus (HIV) disease. Though challenging, application of this technology to anti-tuberculosis treatment could have substantial impact. 

      Health Topics: 
      HIV
      LA/ER Injectable Therapy
      Tuberculosis

        Pages